This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n21http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n4http://linked.opendata.cz/resource/domain/vavai/projekt/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n19http://bibframe.org/vocab/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11310%2F12%3A10126251%21RIV13-GA0-11310___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n20http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11310%2F12%3A10126251%21RIV13-GA0-11310___
rdf:type
skos:Concept n14:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1016/j.pharmthera.2011.07.006
dcterms:description
Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice. Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice.
dcterms:title
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances
skos:prefLabel
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances
skos:notation
RIV/00216208:11310/12:10126251!RIV13-GA0-11310___
n14:predkladatel
n15:orjk%3A11310
n3:aktivita
n13:P n13:I
n3:aktivity
I, P(GAP205/10/0228), P(GAP301/10/0356), P(IAA401990701)
n3:cisloPeriodika
1
n3:dodaniDat
n20:2013
n3:domaciTvurceVysledku
n10:8486573
n3:druhVysledku
n9:J
n3:duvernostUdaju
n6:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
122869
n3:idVysledku
RIV/00216208:11310/12:10126251
n3:jazykVysledku
n17:eng
n3:klicovaSlova
induced cardiomyopathy; doxorubicin interactions; electrochemical biosensor; in-vivo; cytochromes P450; phase-II; peroxidase-mediated oxidation; cell-cycle arrest; metastatic breast-cancer; nanocarriers; adduct formation; ellipticine; anthracyclines
n3:klicoveSlovo
n5:anthracyclines n5:cytochromes%20P450 n5:metastatic%20breast-cancer n5:induced%20cardiomyopathy n5:phase-II n5:electrochemical%20biosensor n5:peroxidase-mediated%20oxidation n5:cell-cycle%20arrest n5:in-vivo n5:doxorubicin%20interactions n5:adduct%20formation n5:ellipticine n5:nanocarriers
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[A68F24C2EDAC]
n3:nazevZdroje
Pharmacology and Therapeutics
n3:obor
n18:FR
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
8
n3:projekt
n4:GAP301%2F10%2F0356 n4:GAP205%2F10%2F0228 n4:IAA401990701
n3:rokUplatneniVysledku
n20:2012
n3:svazekPeriodika
133
n3:tvurceVysledku
Kizek, René Stiborová, Marie Burda, Jaroslav Hraběta, Jan Frei, Eva Adam, Vojtěch Eckschlager, Tomáš Smutný, Svatopluk
n3:wos
000299979600003
s:issn
0163-7258
s:numberOfPages
14
n19:doi
10.1016/j.pharmthera.2011.07.006
n21:organizacniJednotka
11310